Authors


Lung-I Cheng, PhD

Latest:

From Potential to Value: Carving a Slice of the CGT ‘PIE'

The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.


Bhavna Desai

Latest:

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Donielle McCutcheon

Latest:

This is Your Wake-Up Call–Sunshine Act Enforcement is Here

Mitigating potential risk for stakeholders in light of latest Sunshine Act developments.


Clay Romweber, Brand Insights Contributor, EVP, Chief Growth Officer, BioPharm Communications
Clay Romweber, Brand Insights Contributor, EVP, Chief Growth Officer, BioPharm Communications

Latest:

The Importance of Opinion Leader-Content in a Digital Transformation

Marketers are working to reimagine how they leverage key opinion leader (KOL) support during COVID-19.



Amy Brown

Latest:

Identifying Healthcare Trends from Conversation Data

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.





Tracy Duberman, PhD

Latest:

Talent Management Strategies for Post-Milestone Growth

Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives


Josh Canavan, PharmD

Latest:

The Shifting Pharmacy Landscape in 2025

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.



Richard Tillyer, PhD

Latest:

Developing Patient-Focused Solutions: How a Multi-Modality Approach to Drug Discovery and Development is Driving Transformative Innovation

When considering factors like disease biology and patient needs in drug discovery and development, the goal is to deliver effective and scalable treatments globally by balancing established approaches like small molecules or protein therapeutics with more complex modalities such as RNA, cell, and gene therapies.



Kristine Austria Fan

Latest:

3 ASCO Insights for Pharma Communicators

The world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.


Melanie Nelson

Latest:

'Faster, Please': Key Challenges in Chemicals and Materials R&D

Companies must address myriad challenges to improve upon issues such as data quality and transparency, process efficiency, and artificial intelligence/machine learning preparedness.


Lash Group

Latest:

Patient Support Launch Guide: Novel Therapies

Gain actionable insights from Lash Group experts, leveraging 30+ years of experience launching new programs to help you ensure patient support success.



Devesh Verma

Latest:

Omnichannel Marketing Challenges for European Life Sciences Companies: A Data Science Perspective

As EU brand leaders build their omnichannel customer engagement strategies, they need to address challenges in the European environment with a well-thought-out deployment plan.


Joanna Billings, Pharm D

Latest:

How Technology Can be Used to Improve Adherence

Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.


Christopher O'Toole

Latest:

Strategic Commercialization of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle Value

The regulatory environment has become increasingly supportive of multi-indication development.


Elias C. Pittos, PharmD, BCOP

Latest:

Is Community the Next Frontier for Cell and Gene Therapy?

Both community and academic delivery models play essential and complementary roles in expanding CGT access.



Rick Kelly

Latest:

A Pricing Revolution: The State Offensive

The second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.


Wolfgang Liang

Latest:

Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.


Hilary Johnson

Latest:

PREP Act Protections for COVID-19 Vaccine Liability

How PREP Act protections will apply to potential COVID-19 vaccine-related claims.


Shannon Hartley

Latest:

Commercial Models for the Changing Life Sciences Market

Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.


Chris Dowd

Latest:

Copay Adjustment Chess Match: What Will Payers Do Next?

As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.


Sharat Sharan

Latest:

Digital Engagement is Only as Good as the First-Party Data It Provides

First-party insights bridge marketing and sales to deliver better HCP experiences.